DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

NCT06364917 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Pemetrexed
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

University of Alabama at Birmingham